AstraZeneca voted one of top 100 sustainable companies

Amy Schofield 23 January 2018

AstraZeneca has been recognised as one of the 100 most sustainable companies and commended for its renewable energy use.

Toronto-based media and investment advisory firm Corporate Knights named AstraZeneca as one of the top 100 sustainable companies. Meanwhile, an international non-profit organisation focused on accelerating climate action, The Climate Group, recognised the company as one of 122 multinational businesses who have made the RE100 commitment.

The Corporate Knights Global 100 Index is a ranking of the world's most sustainable companies, from 22 countries, across all sectors of the economy. AstraZeneca is ranked 34th globally, placing it in the top 2% of companies for sustainability performance, and ranked third among all UK companies. The latest iteration of the index was announced at the World Economic Forum in Davos, Switzerland. 

The Global 100 uses a quantitative methodology to determine inclusion in the ranking, assessing factors including energy productivity, innovation capacity, safety performance and leadership diversity.

All publicly traded companies with revenues greater than $1 billion are automatically considered, and each organisation is evaluated on a set of up to 17 indicators relative to their industry peers using publicly-available information. 

A new report released in Davos by The Climate Group, ‘Approaching the tipping point: how corporate users are redefining global electricity markets’, tracks progress made in 2016-2017 by companies committed to 100% renewable power and provides insight into emerging trends in corporate sourcing of renewables around the world. 

The report describes AstraZeneca as one of the 'biggest achievers in 2016', increasing its share of renewable electricity more than three-fold.

Katarina Ageborg, Executive Vice President for Sustainability and Chief Compliance Officer, said: “We are proud to be recognised by these two leading, independent organisations for our work to broaden access to healthcare, to minimise the environmental footprint of our products and processes, and to ensure that ethics and transparency underpin everything we do.”


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.